Objectives: To assess the ability of meropenem to potentiate aminoglycoside (AG) activity against laboratory and AG-resistant cystic fibrosis (CF) isolates of Pseudomonas aeruginosa and to elucidate its mechanism of action.
Introduction
Pseudomonas aeruginosa is a common nosocomial pathogen 1, 2 and major cause of morbidity and mortality in patients with cystic fibrosis (CF). [3] [4] [5] Treatment of P. aeruginosa infections is complicated by the organism's impressive resistome of intrinsic and acquired resistance genes, [6] [7] [8] with difficult-to-treat MDR and XDR P. aeruginosa increasingly common. [9] [10] [11] [12] [13] Aminoglycosides (AGs) have an extensive history in the management of P. aeruginosa infections, particularly lung infections in patients with CF. [14] [15] [16] Still, there are longstanding issues with AG toxicity [17] [18] [19] [20] [21] [22] and AG resistance development in the infecting P. aeruginosa, 11, 12, [23] [24] [25] which has limited the utility of these agents. To address these issues, AGs might be more routinely partnered with compounds that potentiate their activity, enabling the use of lower, less toxic 26, 27 doses and/or rendering otherwise resistant strains susceptible. In potentiating AGs versus resistant strains, the major determinants of AG resistance need to be considered. AG-modifying enzymes are major determinants of AG resistance in P. aeruginosa, 28, 29 although, interestingly, they appear to occur infrequently in CF lung isolates, 8, [30] [31] [32] [33] where the MexXY-OprM multidrug efflux system is a major contributor to AG resistance. 28, 29, [34] [35] [36] Thus, AG potentiators that target MexXY-OprM might be useful adjuvants for anti-pseudomonal therapy of CF lung infections. In the current study, we identify a compound, the b-lactam meropenem, which potentiates AG activity against laboratory and clinical isolates of P. aeruginosa. Moreover, this potentiation is mostly absent in a mutant lacking MexXY, an indication that meropenem is somehow targeting this efflux system and compromising its contribution to AG resistance.
Materials and methods

Bacterial strains and growth conditions
The bacterial strains and plasmids used in this study are listed in Table 1 . Plasmid pEX18Tc and its derivatives were maintained in Escherichia coli with 5 (in L-broth) or 10 (on L-agar) mg/L tetracycline. Deletions in mexZ and mexXY were individually engineered into P. aeruginosa DmexB strain K1523 using vectors pYM021 (pEX18Tc::DmexZ) and pCSV05 (pEX18Tc::DmexXY), respectively, as described previously. 37, 38 To engineer an DoprD derivative of WT P. aeruginosa PA01 strain K767, a DoprD derivative of pEX18Tc was first constructed by amplifying, using PCR, 1 kb fragments upstream and downstream of oprD from P. aeruginosa K767 chromosomal DNA and cloning these individually into pEX18Tc, after which the downstream fragment was excised and cloned into pEX18Tc harbouring the upstream fragment. Amplification of the upstream and downstream fragments was achieved using primers oprD-Up-F (5 0 -GCT AGGATCCCGTTGATCGGCAGTTGCTTGTAGC-3 0 ; BamHI site underlined) and oprD-Up-R (5 0 -GATCAAGCTTAAGCTTCTGTCGATCCTGTAATCGACC-3 0 ; tandem HindIII sites underlined), and oprD-Down-F (5 0 -GATCAAGCTTAAGCTTC ATCACTTTCATTGTGATTGCTCC-3 0 ; tandem HindIII sites underlined) and oprD-Down-R (5 0 -GCTAGGTACCAGCGACATTCATCTTGTCCGC-3 0 ; KpnI site underlined), and Vent DNA polymerase (New England Biolabs) in separate 100 lL PCR reaction mixtures formulated as described previously. 39 Following an initial denaturation step at 95 C for 2 min, the mixtures were subjected to 30 cycles of heating at 94 C for 1 min, 60 C for 1 min and 72 C for 1 min, before finishing with a 10 min incubation at 72 C. The PCR fragments were purified, digested with BamHI and HindIII (upstream fragment) or HindIII and KpnI (downstream fragment), individually cloned into pEX18Tc for initial sequencing before excising (as a HindIII-KpnI fragment) and cloning the downstream fragment into the pEX18Tc vector harbouring the upstream fragment. The resultant vector, pEX18T::DoprD, was introduced into E. coli S17-1 and mobilized into P. aeruginosa K767 as before. 37 P. aeruginosa transconjugants harbouring chromosomal inserts of the deletion vector were selected on L-agar plates containing tetracycline (50 mg/L) and chloramphenicol (5 mg/L; to counterselect E. coli S17-1). These were subsequently streaked on to L-agar containing sucrose (10% w/v) as before, 40 with sucrose-resistant colonies screened for the deletion of oprD using colony PCR with 2.5 U Taq polymerase in 10% (v/v) DMSO. 41 Colony PCR was carried out using primers oprD-Up-F and oprD-Down-R.
DNA methods
Standard protocols were used for restriction endonuclease digestions, ligations, transformations and agarose gel electrophoresis, as previously described. 42 Plasmid DNA was extracted from E. coli using the Fermentas GeneJET Plasmid Miniprep Kit or the Qiagen Plasmid Midi Kit according to protocols provided by the manufacturers. Chromosomal DNA was extracted from P. aeruginosa using the Qiagen DNeasy Blood & Tissue Kit according to a protocol provided by the manufacturer. PCR products and restriction endonuclease digest products requiring purification were purified using the Promega Wizard SV Gel and PCR Clean-Up System according to a protocol provided by the manufacturer. CaCl 2 -competent E. coli cells were prepared as previously described. 42 Oligonucleotide synthesis was performed by Integrated DNA Technologies (Coralville, IA, USA) and nucleotide sequencing was performed by the ACGT Corporation (Toronto, Canada).
Compound library screen for potentiators of AG activity WT P. aeruginosa PA01 strain K767 was screened against the Pharmakon-1600 library (Microsource Discovery Systems, Inc.) for agents that rendered the organism susceptible to 1 =4 MIC of the AG paromomycin (64 mg/L) according to CLSI guidelines as described. 43 
Antibiotic susceptibility testing
The susceptibility of P. aeruginosa to antimicrobial agents was assessed using the 2-fold serial microtitre broth dilution method described previously, 44 with an inoculum of $5%10 5 cells/mL. MICs were recorded as the lowest concentration of antibiotic inhibiting visible growth after 18 h of incubation at 37 C. In some experiments the impact of meropenem and additional b-lactams (at 1 =4 and/or 1 =2 MIC) on antibiotic susceptibility was assessed.
Quantitative RT-PCR
RNA was isolated from log phase cells of P. aeruginosa strain K767 exposed or not to 1% MIC paromomycin (K256 mg/L; added at late log phase, 30 min prior to harvesting of cells for RNA isolation) and converted to cDNA as described. 45 In some instances, meropenem was added at 1 =2 MIC (0.5 mg/L) 30 min prior to the addition of paromomycin. Expression of mexX 45 and rpoD 46 was assessed using a previously detailed quantitative RT-PCR protocol. 45 Ethidium bromide accumulation assay Poole et al.
carried out as previously described. 47 Briefly, late exponential cells were harvested at 5000 g for 15 min at room temperature, washed once with 50 mM sodium phosphate buffer (pH 7.0) containing 100 mM NaCl and 0.1% (v/v) glycerol. Cells were then resuspended in the same buffer to an OD 600 of 5. Using an Opti-Plate-96 black opaque microplate (Perkin Elmer), bacterial cells were diluted to a final OD 600 of 1 and the accumulation of ethidium bromide (50 lM final concentration) by P. aeruginosa cells was monitored with a Varioskan microplate reader (Thermo Electron Corporation) at 37 C using the constant agitation setting. The excitation and emission wavelengths were 520 and 590 nm, respectively. In some experiments, meropenem (0.5 mg/L final concentration) was added 30 min prior to harvesting the cells.
Results
Meropenem potentiates paromomycin activity against P. aeruginosa dependent on MexXY A substantial number of chromosomal genes contribute to AG resistance in P. aeruginosa, 48 including the MexXY-OprM multidrug efflux system, [49] [50] [51] which is a major determinant of AG resistance in CF isolates. 29 In an effort to identify agents that target this AG resistance mechanism and, so, improve AG activity against P. aeruginosa, a screen of a limited 1600 compound library was undertaken, looking initially for potentiators of AG activity versus WT P. aeruginosa. Paromomycin was chosen as a representative AG as it demonstrated the greatest difference in MIC between strains carrying versus lacking mexXY, 49 providing a suitably sensitive screen for AG potentiators that targeted this efflux system. The library was screened for agents that rendered WT P. aeruginosa PAO1 strain K767 susceptible to 1 =4 MIC paromomycin for this strain but had no intrinsic antimicrobial activity (at the concentrations being screened). A number of b-lactams were identified amongst several putative AG-potentiating compounds, including a penicillin (piperacillin), a cephalosporin (ceftazidime) and a carbapenem (meropenem). At 1 =4 MIC, ceftazidime showed a modest ability to potentiate paromomycin activity, increasing paromomycin susceptibility only 4-fold (Table 2 ). In contrast, meropenem and piperacillin were superior potentiators, increasing paromomycin susceptibility 8-and 16-fold, respectively, at 1 =4 their MIC and this increased to 16-and 64-fold at 1 =2 MIC (Table 2) . Meropenem potentiation of paromomycin was reduced (2-fold) in a mutant lacking OprD (Table 2) , a major portal for entry of carbapenems, 52 consistent with the drug needing to enter the cell to effect paromomycin potentiation.
To ascertain whether meropenem or piperacillin acted on MexXY in increasing the susceptibility of K767 to paromomycin, a mutant strain lacking this efflux system was assessed for potentiation of paromomycin activity by these b-lactams. The DmexXY mutant strain, K1525, as expected, showed increased susceptibility to paromomycin (Table 2) , consistent with the known contribution of the MexXY-OprM efflux system to intrinsic AG resistance. 53 At 1 =4 their MICs, both b-lactams had only a modest (2-fold) impact on paromomycin susceptibility (Table 2) , an indication that they were potentiating paromomycin activity much more poorly in the absence of MexXY and, so, possibly targeting this efflux system in their potentiation of paromomycin activity in K767. Still, at the higher concentration of 1 =2 MIC, piperacillin substantially increased paromomycin susceptibility in the DmexXY strain while meropenem did not (Table 2) , an indication that while meropenem potentiation was largely dependent on this efflux system, piperacillin potentiation was not. Thus, meropenem was studied further in an effort to understand its link to MexXY.
In a recent report, mexXY expression and its contribution to AG resistance in a clinical isolate was shown to be dependent on the AmgRS two-component system (TCS). 43 To assess, then, whether the nominal MexXY dependence of meropenem potentiation of paromomycin activity reflects targeting of MexXY versus targeting of AmgRS and, further, to assess whether its link to MexXY is specific, meropenem potentiation of paromomycin activity was assessed in the DamgR mutant strain K3159. Again, as expected, loss of amgR enhanced paromomycin susceptibility (Table 2) , consistent with the known contribution of AmgRS to intrinsic AG resistance. 49 Still, meropenem (and, indeed, piperacillin) potentiation of paromomycin activity was still in evidence in strain K3159, with susceptibility to this AG increasing 8-fold in the presence of 1 =4 or 1 =2 MIC of meropenem (Table 2) , consistent with the carbapenem acting specifically on MexXY. In agreement with this, loss of mexXY in the amgR deletion strain largely abrogated meropenem potentiation of paromomycin activity (see K3166, Table 2 ). Interestingly, the DamgR mutant was more susceptible to meropenem (and piperacillin) than its WT parent strain ( Table 2 footnotes), an indication that these b-lactams likely activate this TCS, which protects against the adverse effects of these drugs on the cell wall. The functionally related 54 CpxRA TCS in E. coli is also activated by b-lactams and a cpxR deletion stain is more susceptible to these agents, 55 evidence that it protects E. coli against b-lactams. Potentiation of aminoglycoside activity
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Meropenem potentates the activities of multiple AGs versus P. aeruginosa
To assess whether meropenem generally potentiated AG activity versus strain K767, its impact on susceptibility to additional AGs was also examined. While meropenem enhanced susceptibility to all tested AGs, it did so only marginally for tobramycin (2-fold reduction in MIC) (Table 3) . Interestingly, potentiation was greatest for paromomycin and neomycin, representatives of the 4,5-linked AGs, versus the 4,6-linked AGs (amikacin, gentamicin and tobramycin) ( Table 3 ). In contrast, meropenem strongly potentiated the activities of all tested AGs, including tobramycin, versus a second prototypic strain, PA14 (Tables 2 and 3 ). For all AGs except tobramycin, meropenem had a reduced (2-fold reduction only) impact on AG MICs in the K767 DmexXY strain (K1525 ;  Table 3 ), an indication that for most AGs, potentiation was at least partly MexXY-dependent.
MexXY-dependent carbapenem potentiation of AG activity
MexXY-dependent meropenem potentiation of AG activity may be a unique property of this carbapenem or a property shared more generally by this class of b-lactam. To assess this initially, the impact of imipenem on AG susceptibility was examined and shown to have no effect (Table 4) . Imipenem and meropenem differ in their relative affinities for their PBP targets, with meropenem having a generally higher affinity for PBP3 than imipenem does. 56, 57 It may be, therefore, that targeting PBP3 is somehow central to MexXY-dependent potentiation of AG activity. To test this, carbapenems that do (doripenem 56 ) and do not (biapenem 57 ) bind PBP3 with high affinity were assessed for the ability to potentiate AG (paromomycin) activity versus WT P. aeruginosa as well as the importance of MexXY for any potentiation seen. Intriguingly, doripenem substantially potentiated paromomycin activity (16-fold increase in susceptibility) while biapenem had a minimal impact only (2-fold increase in susceptibility), with doripenem potentiation virtually lost in the absence of mexXY (Table 4) . Thus, targeting of PBP3 may be important for MexXY-dependent AG potentiation by meropenem (and doripenem).
Meropenem does not impede mexXY expression or MexXY-OprM efflux activity
MexXY-OprM contributes to intrinsic AG resistance in P. aeruginosa because of AG induction of the mexXY efflux operon. 37, 53 Thus, one way in which meropenem could potentiate AG activity via MexXYOprM is to interfere with AG-induced expression of mexXY. Still, paromomycin induction of mexX, as a measure of mexXY expression, was retained in the presence of meropenem (Figure 1 ), eliminating this possibility. Alternatively, meropenem could interfere with MexXY-OprM efflux activity. To assess this, a previously described ethidium bromide accumulation assay was carried out using an available DmexB strain (to eliminate the efflux activity of the constitutively expressed 58 MexAB-OprM efflux system) and derivatives expressing (DmexZ; K3795) or lacking (DmexXY; K1542) MexXY. As expected, the MexXY-expressing K3795 strain showed reduced ethidium bromide accumulation as compared with the MexXY-deficient strain K1542 (Figure 2 ), a marker of MexXYmediated efflux in K3795. Exposure of K3795 to meropenem did not, however, influence efflux activity (Figure 2) , an indication that meropenem is not hampering MexXY-OprM pump function.
Meropenem potentiation of AGs versus clinical isolates of P. aeruginosa
To assess the ability of meropenem to potentiate AG activity versus AG-resistant clinical (CF) isolates and the dependence on MexXY for this, the impact of meropenem on AG MICs was examined in several previously reported CF isolates and their DmexXY derivatives. 39 Interestingly, while four of the five isolates showed substantial AG potentiation (MICs reduced at least 4-fold and up to 64-fold) of at least four of the five AGs tested (and all isolates showed 8-to 16-fold potentiation of tobramycin), in three of the cases (K2153, K2160, K2161) this potentiation was maintained in the DmexXY strains (K2165, K2168, K2169) ( Table 5) . Potentiation was, however, greatly reduced in the DmexXY derivatives of strains K2156 (see K2167) and K2161 (see K2169) (Table 5) . Thus, in contrast to the WT laboratory strain K767, clinical isolates exhibited Poole et al.
MexXY-dependent and -independent AG potentiation by meropenem. Examination of a larger number of AG-resistant CF isolates (28) confirmed the general ability of meropenem to potentiate AG activity against CF strains, with 15 of 28 strains showing at least a 4-fold increase in susceptibility to all five tested AGs and a further seven showing a minimum 4-fold increase in susceptibility to four of five AGs (Table 6 ). In general, as with K767, there was greater potentiation of the 4,5-linked versus 4,6-linked AGs and, in addition, there was more consistent potentiation of the 4,5-linked AGs.
Discussion
There is a long history of b-lactam/AG synergism in P. aeruginosa [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] so it is unsurprising that a screen for AG potentiators identified a number of agents of this class. In addition, while there are a few reports of meropenem/AG (mostly amikacin) synergy versus clinical isolates P. aeruginosa, [71] [72] [73] no mechanistic study of this has been undertaken. The observation, here, that meropenem potentiation of AG activity is largely dependent on the MexXY-OprM multidrug efflux system is potentially informative, despite indications that it does not interfere with pump gene expression or pump activity, in contrast with previously described AG potentiators that inhibit MexXY activity. 74, 75 Meropenem may, however, be interfering with some process downstream of but dependent on MexXY, which is also linked to AG susceptibility. We have, for example, recently shown that the MexXY status of the cell impacts LPS biosynthesis, with MexXY expression linked to a reduction in both the synthesis of this macromolecule and the expression of certain LPS modification genes. 76 This is an interesting observation given that LPS deficiency has been linked to AG resistance in this organism 48, 77 and LPS is a known binding target for AGs [78] [79] [80] [81] that is required for AG uptake across the outer membrane (OM) and into cells. 82 One possibility then is that MexXY operation influences the LPS content and/or composition of the OM and this reduces AG binding/uptake and, ultimately, susceptibility, with meropenem somehow interfering with these MexXY-dependent effects on LPS.
b-Lactams (penicillin) have been shown to promote increased uptake of the AG streptomycin in both E. coli 83 and P. aeruginosa, 84 providing one possible explanation for synergy between these agents. In light of our demonstrated involvement of MexXY-OprM in this, it may be that the increased AG accumulation promoted by some b-lactams results from their interference with MexXYdependent effects on LPS that would otherwise limit AG uptake. Still, it is not known whether b-lactam promotion of AG uptake includes other AGs besides streptomycin or extends to nonpenicillin b-lactams (i.e. includes meropenem), so any involvement of MexXY in this is, as yet, uncertain. Moreover, penicillin-promoted streptomycin uptake has also been reported in Gram-positive organisms 85, 86 where an efflux/LPS link is not possible. In addition, b-lactam/AG synergy in the absence of b-lactam-enhanced AG uptake has been noted in some bacteria, 86 an indication that additional mechanisms, possibly involving MexXY-OprM, may contribute to this synergy in P. aeruginosa.
An interesting observation is the striking connection between MexXY and potentiation of AGs by meropenem versus piperacillin, where at all sub-MIC concentrations tested meropenem potentiation of the AG paromomycin was generally MexXY-dependent. Still at 1 =4 MIC, piperacillin potentiation was also nominally MexXYdependent, with potentiation independent of this efflux system only seen at the higher concentration of this b-lactam ( 1 =2 MIC). It may be, therefore, that piperacillin can potentiate in multiple Potentiation of aminoglycoside activity JAC ways both dependent on and independent of MexXY. Of note, there were differences in AG potentiation capability of other carbapenems, with doripenem potentiating paromomycin activity while imipenem and biapenem did not. Intriguingly, meropenem and doripenem and, indeed, piperacillin and ceftazidime, all of which showed some MexXY dependence in their potentiation of paromomycin activity, all bind PBP3 with high affinity. 56, 57, 87 PBP3 is specifically involved in septal murein synthesis during cell division, 88, 89 and there are clear operational links between the peptidoglycan and OM during cell division that serve to co-ordinate invagination across the tripartite Gram-negative cell envelope. 90 It would not be surprising, therefore, for b-lactam-mediated perturbation of cell division peptidoglycan synthesis to impact the OM, possibly in ways that alter (i.e. enhance) AG binding and penetration of the OM, and in so doing abrogate the possible resistance-promoting MexXY effects on LPS.
The link between b-lactams and MexXY-dependent potentiation of AG activity has obvious relevance in the context of AG resistance in CF, where this efflux system is a common determinant of AG resistance in P. aeruginosa lung isolates. 29, 34, 36 It remains be seen, however, what specific MexXY-mediated changes are manifest in the LPS, whether and how these might alter AG binding and uptake, and whether and how b-lactams short-circuit this. Clearly, however, b-lactam potentiation of AGs can occur independently of this efflux system, highlighting the mechanistic complexity of blactam/AG synergy.
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